The following is a summary of the “Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273,” published in the January 2023 issue of Allergy and Clinical Immunology by Ailsworth, et al.
The purpose of this study was to compare the size and duration of S-RBD immunoglobulin (Ig)G levels following the booster mRNA vaccination dose to those seen following the primary series. In addition, s-RBD IgG levels were compared between BNT162b2 and mRNA-1273 boosters, and the effects of age and previous infection were investigated.
Adults in a work-based cohort submitted serum and filled out questionnaires around the time they received their 2nd and 3rd doses of homologous mRNA vaccination; these samples and responses included data on whether or not the participants had previously been infected with COVID-19. They utilized an ImmunoCAP-based technique to quantify IgG to S-RBD. In addition, a commercial assay measured igG to the SARS-CoV-2 nucleocapsid in a subset of samples.
About 228 participants had samples taken between 7 and 150 days after their primary series vaccine, and an additional 117 subjects had samples taken between 7 and 150 days following their boost. Booster doses of the COVID-19 mRNA vaccine increase antibody persistence, indicating better long-term clinical protection against SARS-CoV-2 infection compared to the 2-dose regimen.
Source: sciencedirect.com/science/article/pii/S1081120622018294